Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension

This study examined the dose-response characteristics of aprocitentan, a dual endothelin A/endothelin B receptor antagonist, in patients with essential hypertension. In a randomized, double-blind, parallel study design, eligible patients with a sitting diastolic blood pressure (BP) of 90–109 mm Hg r...

Descripción completa

Detalles Bibliográficos
Autores principales: Verweij, Pierre, Danaietash, Parisa, Flamion, Bruno, Ménard, Joël, Bellet, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott, Williams & Wilkins 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098434/
https://www.ncbi.nlm.nih.gov/pubmed/32063059
http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.14504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098434/
https://www.ncbi.nlm.nih.gov/pubmed/32063059
http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.14504

Ejemplares similares